in both sexes. In our analysis we used descriptive statistics, independent samples t-test. Results: In 1990, standardized mortality in men 45-59 was the highest in fSU (n=15) 358.69/100,000, the lowest rate was found in WE (n=17) 143.67/100,000. It significantly decreased to 244.99/100,000 (-31.70%, n=11) and 50.29/100,000 (-65.00%, n=15) by 2014 respectively (p,0.05). In 1990, standardized mortality in women 45-59 was the highest in fSU (n=15) 99.78/100,000, the lowest rate was found in WE (n=17) 29.06/100,000. It significantly decreased to 56.26/100,000 (-43.61%, n=11) and 9.89/100,000 (-65.97%, n=15) by 2014 respectively (p,0.05). Mortality also decreased significantly (p,0.001) among men (-49.41%) and women (-50.57%) in EE between 1990 and 2014. Conclusions: A significant decline was detected in standardized mortality of IHD in both sexes aged 45-59 between the assessed time period. The highest improvement was observed in Western-European countries.

Objectives: To estimate the prevalence of Juvenile Idiophatic Arthritis (JIA) in Colombia. Methods: This cross-sectional study identified patients with a diagnosis code for AIJ (ICD-10 M08-M09) using a nationally-representative database of health care resource utilization provided by the "Sistema Integral de Información de la Protección Social (SISPRO)" in 2017. In addition, estimated prevalence was contrasted using data of personal history of JIA using a database of patients with # 16 years affiliated to a subsidized-regime insurance company (N = 397,160) of the Caribbean region of Colombia. The estimated prevalences were extrapolated to the overall Colombian population using the demographic projections of individuals with # 16 years of age (14,588,845) provided by the Departamento Administrativo Nacional de Estadisticas (DANE). Results: In 2017, the prevalence of JIA in the subsidized-regime company was 13 per 100,000 (52/397.160). According to the data of SISPRO the prevalence of JIA in Colombia was 10.9 per 100,000 (1,602/14,588,845). Extrapolating these estimations to the general population of Colombia, the estimated number of prevalent cases of JIA in Colombia could be approximately 1.602 and 1.896 cases, respectively. Conclusions: These estimations are lower in Colombia compared to previously reported prevalence globally (between 60 and 400 cases per 100,000).

whichever was earlier. Cox regression analyses were used to examine the impact of switching to another OAC (vs. continuing apixaban) on the risk of MB-related or stroke/SE-related hospitalization during follow-up, while controlling for differences in patient characteristics. Results: Among 7,858 elderly NVAF patients who initiated treatment with apixaban included in the study, 14% (N=1,110; mean age: 78 years; 51% male) were Switchers; 86% (N=6,748; mean age: 79 years; 46% male) were Continuers. Switchers had higher unadjusted rates of MB-related (8.2% vs. 2.2%; p,0.001) and stroke/SE-related (3.2% vs. 1.4%, p,0.001) hospitalization vs. Continuers during follow-up. Cox regression models showed that apixaban Switchers vs. Continuers had a significantly greater risk of MB-related hospitalization (hazard ratio [HR]: 2.0; 95% CI: 1.5-2.6; p,0.001) during follow-up; the risk of stroke/SE hospitalization did not significantly differ (HR: 1.4, 95% CI: 0.9-2.1, p=0.15). Conclusions: In the real-world setting in the US, among elderly NVAF patients who initiated apixaban treatment, there was an association between switching to another OAC and a higher rate of MB-related hospitalization during follow-up compared to continuing the treatment.

Background: Patients undergoing percutaneous transluminal coronary angioplasty (PTCA) with drug eluting stent (DES) for acute coronary syndrome (ACS) are recommended dual antiplatelet drugs (APs) for a minimum of 12 months after the procedure to prevent stent thrombosis. However antiplatelet effect may not be identical. Some patients show non-responsiveness to APs and therefore may be at risk of catastrophic events. Lab assessment of platelet response may identify patients at higher risk. Objectives: Assessment of antiplatelet drug resistance using thromboelastography and its correlation with major adverse cardiac events (MACE) up to 90 days. Methods: We conducted a prospective observational cohort study in a tertiary care center in South India including adult patients with acute coronary syndrome (ACS) who underwent primary PTCA with DES and were not on any antiplatelet drugs previously. Whole blood thromboelastography (TEG) with platelet mapping using arachidonic acid (AA) and adenosine diphosphate (ADP) as reagents was performed to assess the platelet response to aspirin and ticagrelor respectively within 24 hours after PTCA. MACE were observed for up to 90 days. Results: Fifty six patients with mean age of 58.8610.9 years were included of whom 72.4% were male. Nine (16.1%) patients showed a low response or no-response to ADP and 4 (7.1%) patients showed a low response or no-response to AA. Clinical MACE was seen in 6 (10.7%) of the patients, out of which 4 (66.7%) events occurred in those with abnormal platelet response to ticagrelor. Only one patient was not compliant to medications but no MACE occurred in that patient. Association between occurrence of MACE and abnormal platelet response to ticagrelor was significant (P= 0.002). However, association between MACE and platelet response to aspirin was not significant. Conclusions: TEG is relatively new investigational approach to assess the ticagrelor non-responsiveness. Abnormal platelet response detected by TEG-platelet mapping was associated with major adverse cardiac events.

income, longer diabetes duration, insulin treatment, and comorbidities. Subjects without problems based on the items of the HINT-8 showed higher mean scores than subjects with problems in EQ-5D-5L index (p,0.01), EQ VAS (p,0.05), SF-36v2 (scale/component summary) (p,0.01) and SF-6D index (p,0.01). The Pearson correlation coefficient between the HINT-8 and the EQ-5D-5L index was 0.715 (p,0.01), and that between the HINT-8 index and the EQ VAS was 0.517 (p,0.01). Correlations between HINT-8 index and SF-36v2 scale scores were highest in bodily pain (r=0.669, r,0.01) and lowest in role emotional (r=0.478, p,0.01). The correlation coefficient between HINT-8 index and SF-6D index was 0.724 (p,0.01). Kappa values of the HINT-8 ranged from 0.342 to 0.634; the ICC was 0.800 (CI 0.720, 0.860). Conclusions: This study showed good measurement properties of the HINT-8 in patients with DM.